As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Sanofi and CD&R sign Opella share purchase agreementParis, February 19, 2025. Following completion of the required social and corporate ...

Sanofi and Johnson & Johnson ended development of an experimental vaccine after it failed to adequately protect against an ...

Deal-starved banks lined up to make concessions to get a slice of Europe’s biggest buyout debt deal last year. They also put ...

A year and a half after Sanofi swooped in on Johnson & Johnson’s dismantled vaccines unit to pick up an E. coli candidate, ...

Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the supplemental biologics license application for ...

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...